Quest Laboratories Limited (NSE: QUESTLAB) is a Dhar, Madhya Pradesh-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹147 Cr, it ranks #2,906 by market cap among the 6,197 Indian listed companies on FinBizNet, and #13 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹92.90 (as of 16 Nov 2026), the share price is 39.1% below its 52-week high of ₹152.60 and 35.4% above its 52-week low of ₹68.60. The share price is up 5.8% over one year and up 0.6% over three months.
| Current Price | ₹92.90 |
|---|---|
| Market Cap | ₹147 Cr |
| NSE Symbol | QUESTLAB |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 10.2 |
| Return on Equity | 16.82% |
| Return on Assets | 9.39% |
| 52-Week Range | ₹68.60 – ₹152.60 |
| 1-Year Price Change | +5.8% |
| 3-Month Price Change | +0.6% |
| Beta (1Y) | 0.58 |
| Headquarters | Dhar, Madhya Pradesh |
| Website | questlabltd.com |
| Revenue | ₹32 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 8.9% |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Quest Laboratories Limited reported revenue of ₹32 Cr in Q4 FY26, up 5.9% from ₹31 Cr in Q3 FY26. It posted a net profit of ₹3 Cr for the quarter, against a net profit of ₹4 Cr in Q3 FY26 (down 28.8%). Across the 4 quarters from Q1 FY26 to Q4 FY26, quarterly revenue ranged from ₹23 Cr (Q1 FY26) to ₹32 Cr (Q4 FY26). The company was profitable in each of these 4 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q4 FY26 | ₹32 Cr | ₹3 Cr | 8.9% |
| Q3 FY26 | ₹31 Cr | ₹4 Cr | 13.2% |
| Q2 FY26 | ₹26 Cr | ₹4 Cr | 15.7% |
| Q1 FY26 | ₹23 Cr | ₹4 Cr | 17.7% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 66.78% of Quest Laboratories Limited's shares as of Mar 2026, against 66.21% in Mar 2025 (+0.57 percentage points).
Quest Laboratories Limited manufactures and sells pharmaceutical formulations in India. The company offers ethical drugs, generic drugs, and over the-counter drugs under various categories, such as antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and others. It provides its products in various forms, such as tablets, liquid orals, oral dry powders, oral powders, ointments, external liquids, and oral suspension. The company also engages in contract manufacturing activities for pharmaceutical companies. Quest Laboratories Limited was founded in 1994 and is based in Dhar, India.
1. Drugs And Chemicals-This segment engages in the manufacturing of pharmaceutical formulations across a spectrum, including antibiotics, antimalarial, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and others. It produces various products, which include ethical drugs, generic drugs, and over-the-counter drugs in various forms, such as tablets, liquid orals, oral dry powders, oral powders, ointments, and external liquids. 2. NA-NA 3. NA-NA 4. NA-NA
1. Drugs And Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Quest Laboratories Limited | ₹147 Cr | 10.2 | 16.82% | ₹32 Cr | +5.8% |
Listed by market capitalisation. Ratios are shown for context only.
Quest Laboratories Limited is trading at ₹92.90, with a market capitalisation of ₹147 Cr.
Quest Laboratories Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Quest Laboratories Limited has a P/E of 10.2 and a return on equity of 16.82%.
Quest Laboratories Limited is listed on the NSE under the symbol QUESTLAB.
Quest Laboratories Limited's share price is up 5.8% over one year and up 0.6% over three months. Its 52-week range is ₹68.60 to ₹152.60.
In Q4 FY26, Quest Laboratories Limited reported revenue of ₹32 Cr and net profit of ₹3 Cr (standalone, parsed from the company's exchange filing).
Promoters held 66.78% of Quest Laboratories Limited's shares as of Mar 2026, against 66.21% in Mar 2025 (+0.57 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.